The European Commission has approved its seventh Advanced Purchase Agreement (APA) with a pharmaceutical company to ensure access to a potential vaccine against COVID-19 in Q4 of 2021 and in 2022. Under this contract, Member States will be able to purchase up to 100 million doses of the Novavax vaccine, with an option for 100…
The European Commission has approved a fifth contract with the European pharmaceutical company CureVac, which provides for the initial purchase of 225 million doses on behalf of all EU Member States, plus an option to request up to a further 180 million doses, to be supplied once a vaccine has proven to be safe and…
The European Commission says it has concluded exploratory talks with CureVac to purchase a potential vaccine against COVID-19. This is following the positive steps with Sanofi-GSK on 31 July and Johnson and Johnson on 13 August and the signature of an Advance Purchase Agreement with AstraZeneca on 14 August. The envisaged contract with CureVac would…
